Liquidia extends treprostinil promotion pact with Sandoz to 2032, adjusts profit sharing

Liquidia Corp

Third Amendment with Sandoz extends Promotion Agreement initial term to December 31, 2032.
Parties will enter a New Pump Development Agreement for subcutaneous treprostinil pump; development costs and milestones split 50/50.
Profit sharing amended: if aggregate net profits <$500M by Dec 31, 2028, Liquidia PAH receives 50% of net profits thereafter.
Indemnification terms added regarding the new pump development.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liquidia Corp amended Third Amendment to Promotion Agreement with Sandoz Inc. (effective 2022-11-18).

Action: amendment
Agreement: collaboration
Counterparty: Sandoz Inc.
Effective: 2022-11-18

Exact text from the filing

On November 18, 2022, Liquidia PAH, LLC, a Delaware limited liability company (formerly known as RareGen, LLC) (“Liquidia PAH”) and wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Third Amendment to Promotion Agreement (the “Third Amendment”) with Sandoz Inc. (“Sandoz”).

View on SEC.gov

Browse all material agreements →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-122076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.